Claims
- 1. A pharmaceutical composition comprising an effective selective kinase inhibitory amount of a compound of general formula (I):
- 2. A compound of formula (I) according to claim 1, but excluding the compounds 2-phenyl-1H-pyrrolo[2,3-b]pyridine, 2-(4-bromo-phenyl)-3-methyl-1H-pyrrolo[2,3-b]pyridine, 4-(3-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-benzoic acid methyl ester, 2-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine, 2-(4-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine, 5-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridine, 4-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridine, 2-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine, 4-(3-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-benzoic acid, 2-(4-methoxy-phenyl)-3-methyl-1H-pyrrolo[2,3-b]pyridine, 2-(4-methyl-phenyl)-3-methyl-1H-pyrrolo[2,3-b]pyridine, 4-(3-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-benzoic acid isopropyl ester, 2-phenyl-3-methyl-1H-pyrrolo[2,3-b]pyridine, 6-phenyl-5H-pyrrolo[2,3-b]pyrazine, 6-(4-methoxy-phenyl)-5H-pyrrolo[2,3-b]pyrazine, 6-(4-chloro-phenyl)-5H-pyrrolo[2,3-b]pyrazine, 6-(2-chloro-phenyl)-5H-pyrrolo[2,3-b]pyrazine, 3-methyl-6-phenyl-5H-pyrrolo[2,3-b]pyrazine, 2-methyl-6-phenyl-5H-pyrrolo[2,3-b]pyrazine and 7-methyl-6-phenyl-5H-pyrrolo[2,3-b]pyrazine.
- 3. A compound according to claim 2 in which R1 is optionally substituted heteroaryl.
- 4. A compound according to claim 3 in which R1 is optionally substituted azaheteroaryl.
- 5. A compound according to claim 2 in which R1 is optionally substituted indolyl, optionally substituted furanyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted imidazolyl, optionally substituted indazolyl, optionally substituted indolizinyl, optionally substituted tetrahydroindolizinyl or optionally substituted indazolinyl.
- 6. A compound according to claim 3 in which the optionally substituents within R1 are one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, aryl, carboxy (or an acid bioisostere), cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, R4, —C(═O)—R4, —C(═O)—NY1Y2, —C(═O)—OR5, —NY1Y2 and —OR4.
- 7. A compound according to claim 2 in which R1 is optionally substituted aryl.
- 8. A compound according to claim 7 in which R1 is phenyl substituted by one or more groups selected from alkylenedioxy, halo, R4, —NY1Y2 and —OR4.
- 9. A compound of formula (Ia):
- 10. A compound according to claim 9 in which R2 is hydrogen.
- 11. A compound according to claim 9 in which R3 is hydrogen, optionally substituted aryl or lower alkyl.
- 12. A compound of formula (Ib):
- 13. A compound according to claim 12 in which R2 is hydrogen.
- 14. A compound according to claim 12 in which R3 is hydrogen, optionally substituted aryl or lower alkyl.
- 15. A compound of formula (Ic):
- 16. A compound according to claim 15 in which R2 is hydrogen.
- 17. A compound according to claim 15 in which R3 is hydrogen, optionally substituted aryl or lower alkyl.
- 18. A compound of formula (Id):
- 19. A compound according to claim 18 in which R2 is hydrogen, lower alkyl, lower alkyl substituted by —CONY3Y4, lower alkyl substituted by carboxy, lower alkyl substituted by tetrazolyl or lower alkyl substituted by hydroxy.
- 20. A compound according to claims 18 in which R3 is hydrogen, optionally substituted aryl or lower alkyl.
- 21. A compound according to claim 2 selected from the group consisting of:
6-(5-methoxy-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine; 1-[1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-5-yloxy]-cyclobutanecarboxylic acid amide; 2-(5-methoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile; {1-[1-methyl-3-(5H-pyrrolo[2,3-b]pyrazin-6-yl)-1H-indol-5-yloxy]-cyclobutyl}-methanol; or a prodrug, or a pharmaceutically acceptable salt or solvate of said compound, or a prodrug of said salt or solvate.
- 22. A compound according to claim 2 or a corresponding prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or a prodrug thereof, for use in therapy.
- 23. A compound according to claim 2 or a corresponding prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or a prodrug thereof, for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Syk kinase.
- 24. A composition according to claim 1 for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Syk kinase.
- 25. A composition according to claim 1 for use in the treatment of inflammatory diseases.
- 26. A composition according to claim 1 for use in the treatment of asthma.
- 27. A composition according to claim 1 for use in the treatment of psoriasis.
- 28. A composition according to claim 1 for use in the treatment of joint inflammation.
- 29. A composition according to claim 1 for use in the treatment of inflammatory bowel disease.
- 30. Use of a compound according to claim 2 or a corresponding prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or a prodrug thereof, in the manufacture of a medicament for the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Syk kinase.
- 31. Use of a compound according to claim 2 or a corresponding prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or a prodrug thereof, in the manufacture of a medicament for the treatment of asthma.
- 32. Use of a compound according to claim 2 or a corresponding prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or a prodrug thereof, in the manufacture of a medicament for the treatment of psoriasis.
- 33. Use of a compound according to claim 2 or a corresponding prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or a prodrug thereof, in the manufacture of a medicament for the treatment of joint inflammation.
- 34. Use of a compound according to claim 2 or a corresponding prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or a prodrug thereof, in the manufacture of a medicament for the treatment of inflammatory bowel disease.
- 35. A method for the treatment of a human or non-human animal patient suffering from, or subject to, conditions which can be ameliorated by the administration to said patient of an inhibitor of Syk kinase—comprising administering to said patient an effective amount of a compound according to claim 2 or a corresponding prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or a prodrug thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9930698.7 |
Dec 1999 |
GB |
|
Parent Case Info
[0001] This application is a divisional application of U.S. application Ser. No. 10/178,667, filed Jun. 24, 2004, which is a continuation of International Application No. PCT/GB00/04933, filed Dec. 27, 2000 which claims the priority from earlier filed applications GB 9930698.7, filed Dec. 24, 1999 and U.S. Provisional Application No. 60/215,818, filed Jul. 5, 2000. The content of the above-identified applications is incorporated herein in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60215818 |
Jul 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10178667 |
Jun 2002 |
US |
Child |
10827978 |
Apr 2004 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/GB00/04933 |
Dec 2000 |
US |
Child |
10178667 |
Jun 2002 |
US |